Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SNDX – Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.
SNDX
$9.24
Name : Syndax Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $795,077,952.00
EPSttm : -3.85
finviz dynamic chart for SNDX
Syndax Pharmaceuticals, Inc.
$9.24
2.21%
$0.2

Float Short %

26.68

Margin Of Safety %

Put/Call OI Ratio

0.76

EPS Next Q Diff

0.07

EPS Last/This Y

0.01

EPS This/Next Y

1.14

Price

9.03

Target Price

34.18

Analyst Recom

1.25

Performance Q

-33.33

Relative Volume

1.42

Beta

0.72

Ticker: SNDX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02SNDX10.980.915.9130082
2025-06-03SNDX11.190.8814.2529648
2025-06-04SNDX10.970.883.8029646
2025-06-05SNDX11.160.8827.7129658
2025-06-06SNDX11.450.950.0230846
2025-06-09SNDX11.090.950.2230895
2025-06-10SNDX11.230.935.4031148
2025-06-11SNDX10.90.920.3231229
2025-06-12SNDX10.670.9215.2231214
2025-06-13SNDX10.240.958.1131749
2025-06-16SNDX9.990.964.2331813
2025-06-17SNDX9.640.961.1331914
2025-06-18SNDX9.690.960.1231991
2025-06-20SNDX9.470.966.7432082
2025-06-23SNDX9.190.910.0328169
2025-06-24SNDX9.220.860.1727895
2025-06-25SNDX8.90.800.3229196
2025-06-26SNDX9.290.800.0029522
2025-06-27SNDX9.020.760.0630710
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02SNDX10.98-23.4-22.9-3.71
2025-06-03SNDX11.19-23.4-6.1-3.71
2025-06-04SNDX10.96-23.420.9-3.71
2025-06-05SNDX11.16-23.4-5.8-3.71
2025-06-06SNDX11.45-23.4-10.5-3.71
2025-06-09SNDX11.09-23.427.3-3.71
2025-06-10SNDX11.23-23.4-1.7-3.71
2025-06-11SNDX10.89-23.427.5-3.71
2025-06-12SNDX10.67-23.421.9-3.71
2025-06-13SNDX10.23-23.435.9-3.71
2025-06-16SNDX9.98-23.427.1-3.71
2025-06-17SNDX9.63-23.435.1-3.71
2025-06-18SNDX9.69-23.42.8-3.71
2025-06-20SNDX9.48-23.424.9-3.71
2025-06-23SNDX9.18-23.433.9-3.71
2025-06-24SNDX9.20-23.46.4-3.71
2025-06-25SNDX8.90-23.437.6-3.71
2025-06-26SNDX9.30-23.4-34.6-3.71
2025-06-27SNDX9.03-23.431.6-3.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02SNDX-0.083.5026.35
2025-06-03SNDX-0.083.5026.35
2025-06-04SNDX-0.083.5026.35
2025-06-05SNDX-0.083.5026.35
2025-06-06SNDX-0.083.5026.35
2025-06-09SNDX-0.083.4426.35
2025-06-10SNDX-0.083.4426.35
2025-06-11SNDX-0.083.4428.06
2025-06-12SNDX-0.083.4428.06
2025-06-13SNDX-0.083.4428.06
2025-06-16SNDX-0.083.3928.06
2025-06-18SNDX-0.083.3928.06
2025-06-20SNDX-0.083.3928.06
2025-06-23SNDX-0.083.3728.06
2025-06-24SNDX-0.083.3728.06
2025-06-25SNDX-0.083.3728.06
2025-06-26SNDX-0.083.3726.68
2025-06-27SNDX-0.083.3726.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.98

Avg. EPS Est. Current Quarter

-0.99

Avg. EPS Est. Next Quarter

-0.91

Insider Transactions

-0.08

Institutional Transactions

3.37

Beta

0.72

Average Sales Estimate Current Quarter

27

Average Sales Estimate Next Quarter

33

Fair Value

Quality Score

44

Growth Score

34

Sentiment Score

14

Actual DrawDown %

69.7

Max Drawdown 5-Year %

-69.3

Target Price

34.18

P/E

Forward P/E

PEG

P/S

17.79

P/B

3.62

P/Free Cash Flow

EPS

-3.87

Average EPS Est. Cur. Y​

-3.71

EPS Next Y. (Est.)

-2.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-757.52

Relative Volume

1.42

Return on Equity vs Sector %

-177.9

Return on Equity vs Industry %

-160

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

31.6
Syndax Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today
news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance
stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market
stock prices SNDX premarket after hours
ticker SNDX fair value insiders trading